Sagimet Biosciences Inc/$SGMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sagimet Biosciences Inc
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
- Ticker
- $SGMT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 16
- Headquarters
- San Mateo, United States
- Website
- www.sagimet.com
SGMT Metrics
BasicAdvanced
$584m
-
-$1.25
3.40
-
Price and volume
Market cap
$584m
Beta
3.4
52-week high
$10.06
52-week low
$4.50
Average daily volume
1.1m
Financial strength
Current ratio
45.025
Quick ratio
44.312
Long term debt to equity
0.725
Total debt to equity
0.757
Profitability
Management effectiveness
Return on assets (TTM)
-16.41%
Return on equity (TTM)
-24.37%
Valuation
Price to book
2.26
Price to tangible book (TTM)
2.26
Price to free cash flow (TTM)
-8.483
Free cash flow yield (TTM)
-11.79%
Free cash flow per share (TTM)
-1.107
Growth
Earnings per share change (TTM)
-32.25%
3-year earnings per share growth (CAGR)
-79.77%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.